Canada markets open in 5 hours 9 minutes
  • S&P/TSX

    19,258.32
    +195.41 (+1.03%)
     
  • S&P 500

    3,900.11
    -11.63 (-0.30%)
     
  • DOW

    31,438.26
    -62.42 (-0.20%)
     
  • CAD/USD

    0.7795
    +0.0026 (+0.34%)
     
  • CRUDE OIL

    110.73
    +1.16 (+1.06%)
     
  • BTC-CAD

    26,786.47
    -795.31 (-2.88%)
     
  • CMC Crypto 200

    455.47
    -6.32 (-1.37%)
     
  • GOLD FUTURES

    1,828.70
    +3.90 (+0.21%)
     
  • RUSSELL 2000

    1,771.74
    +6.01 (+0.34%)
     
  • 10-Yr Bond

    3.1940
    0.0000 (0.00%)
     
  • NASDAQ futures

    12,084.00
    +43.50 (+0.36%)
     
  • VOLATILITY

    27.10
    -0.13 (-0.48%)
     
  • FTSE

    7,337.18
    +78.86 (+1.09%)
     
  • NIKKEI 225

    27,049.47
    +178.20 (+0.66%)
     
  • CAD/EUR

    0.7361
    +0.0025 (+0.34%)
     

ImmunoGen Announces Webcasts of Presentations at Upcoming Conferences

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

WALTHAM, Mass., May 25, 2022--(BUSINESS WIRE)--ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the following presentations by Company management at upcoming investor conferences will be webcast:

  • William Blair 42nd Annual Growth Stock Conference
    June 8 at 11:20am CT / 12:20pm ET

  • Jefferies Healthcare Conference
    June 9 at 9:30am ET

A webcast of each presentation will be accessible through the "Investors and Media" section of the Company’s website, www.immunogen.com. Following the live webcast, a replay will be available at the same location.

ABOUT IMMUNOGEN

ImmunoGen is developing the next generation of antibody-drug conjugates (ADCs) to improve outcomes for cancer patients. By generating targeted therapies with enhanced anti-tumor activity and favorable tolerability profiles, we aim to disrupt the progression of cancer and offer our patients more good days. We call this our commitment to TARGET A BETTER NOW™.

Learn more about who we are, what we do, and how we do it at www.immunogen.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220525005263/en/

Contacts

INVESTOR RELATIONS AND MEDIA
ImmunoGen
Courtney O'Konek
781-895-0600
courtney.okonek@immunogen.com

OR

FTI Consulting
Robert Stanislaro
212-850-5657
robert.stanislaro@fticonsulting.com

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting